596 related articles for article (PubMed ID: 23394974)
1. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
2. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
3. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching acute treatment on disability in migraine patients using triptans.
Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
[TBL] [Abstract][Full Text] [Related]
5. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
7. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Buse DC; Serrano D; Holland S; Reed ML
Headache; 2013 Sep; 53(8):1300-11. PubMed ID: 23879870
[TBL] [Abstract][Full Text] [Related]
8. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
[TBL] [Abstract][Full Text] [Related]
9. Opioid use and dependence among persons with migraine: results of the AMPP study.
Buse DC; Pearlman SH; Reed ML; Serrano D; Ng-Mak DS; Lipton RB
Headache; 2012 Jan; 52(1):18-36. PubMed ID: 22268775
[TBL] [Abstract][Full Text] [Related]
10. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
11. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
12. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
[TBL] [Abstract][Full Text] [Related]
13. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Serrano D; Buse DC; Manack Adams A; Reed ML; Lipton RB
Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
Lipton RB; Hutchinson S; Ailani J; Reed ML; Fanning KM; Manack Adams A; Buse DC
Headache; 2019 Nov; 59(10):1762-1772. PubMed ID: 31544244
[TBL] [Abstract][Full Text] [Related]
15. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
Headache; 2004; 44(7):661-8. PubMed ID: 15209687
[TBL] [Abstract][Full Text] [Related]
16. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
17. A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.
Landy SH; Turner IM; Runken MC; Lee M; Sulcs E; Bell CF
Headache; 2013; 53(7):1134-46. PubMed ID: 23773016
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Loder EW; Gorman JA; Stewart WF; Reed ML; Fanning KM; Serrano D; Lipton RB
Headache; 2013 Sep; 53(8):1278-99. PubMed ID: 23808666
[TBL] [Abstract][Full Text] [Related]
19. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
Lee JH; Shewale AR; Barthold D; Devine B
Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoepidemiology of triptans in a headache centre.
Ferrari A; Spaccapelo L; Sternieri E
Cephalalgia; 2010 Jul; 30(7):847-54. PubMed ID: 20647176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
